SEC Form 3 · accession 0000919574-26-004386
Pyxis Oncology, Inc. · PYXS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
GordonMD Global Investments LP
10% Owner
GordonMD Long Biased GP LLC
10% Owner
GordonMD Long Biased Master Fund LP
10% Owner
Craig D Gordon
10% Owner
Period of report
Jun 30, 2026
Accepted (ET)
Jul 10, 2026 · 4:10 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001782223
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.001 per shareF1 | holding | — | — | — | 10,024,909 | I | See footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock Purchase WarrantF3,F2 | $3.289 | holding | — | — | — | — | Jul 2, 2029 | Common Stock, par value $0.001 per share | 4,900,039 | — | D |
Explanation of responses
- F1The securities to which this filing relates are held directly by GordonMD Long Biased Master Fund LP (the "Master Fund") to which GordonMD Global Investments LP (the "Investment Manager") serves as investment manager. Craig D. Gordon ("Mr. Gordon") is the managing member of GordonMD Long Biased GP LLC (the "GP"), the general partner of the Master Fund. Each of the Master Fund, the GP and Mr. Gordon disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any.
- F2The Common Stock Purchase Warrant is exercisable on or after the earlier of (i) the date on which the Issuer first publicly discloses clinical data from its micvotabart pelidotin (MICVO) Phase 1 monotherapy study in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) and (ii) October 1, 2026.
- F3Exercise price of $3.289, subject to adjustments as set forth in the Common Stock Purchase Warrant.